Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | FOS | P01100 | 1/20 | 0.32 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205966 | 0.89 | FFAR4 (0.37) | FFAR1FFAR4GPR88FOSJUN | |
| SCHEMBL26205926 | 0.85 | FFAR1 (0.42) | TSHRFFAR1FFAR4GPR88 | |
| SCHEMBL22525462 | 0.82 | AAK1 (0.39) | GPR88 | |
| SCHEMBL30169032 | 0.82 | AAK1 (0.39) | GPR88 | |
| SCHEMBL26205965 | 0.82 | TSHR (0.43) | TSHRFFAR1FFAR4FOSJUN | |
| SCHEMBL26205927 | 0.82 | FFAR1 (0.40) | FFAR1FOSJUN | |
| SCHEMBL26205964 | 0.81 | FFAR1 (0.34) | TSHRFFAR1FFAR4GPR88FOS | |
| SCHEMBL26205954 | 0.80 | CYSLTR2 (0.35) | TSHRPLA2G2AFFAR1FOSJUN | |
| SCHEMBL26205940 | 0.79 | ACACB (0.36) | — | |
| SCHEMBL26205938 | 0.79 | CYSLTR2 (0.35) | PLA2G2AFFAR4FOSJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | TSHR 1768/4885PLA2G2A 4062/4885FFAR1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.